| Literature DB >> 35590042 |
Nathan A Shlobin1,2, Josemir W Sander3,4,5,6.
Abstract
Drug-resistant epilepsy is associated with poor health outcomes and increased economic burden. In the last three decades, various new antiseizure medications have been developed, but the proportion of people with drug-resistant epilepsy remains relatively unchanged. Developing strategies to address drug-resistant epilepsy is essential. Here, we define drug-resistant epilepsy and emphasize its relationship to the conceptualization of epilepsy as a symptom complex, delineate clinical risk factors, and characterize mechanisms based on current knowledge. We address the importance of ruling out pseudoresistance and consider the impact of nonadherence on determining whether an individual has drug-resistant epilepsy. We then review the principles of epilepsy drug therapy and briefly touch upon newly approved and experimental antiseizure medications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35590042 DOI: 10.1007/s40263-022-00922-4
Source DB: PubMed Journal: CNS Drugs ISSN: 1172-7047 Impact factor: 6.497